Beta cell derived cholecystokinin drives obesity associated pancreatic adenocarcinoma development

Pancreatic endocrine-exocrine crosstalk plays a key role in normal physiology and disease and can be altered by host metabolic states, such as obesity. Classically, endocrine islet beta (β) cell secretion of insulin promotes the development of obesity-associated pancreatic adenocarcinoma (PDAC), an exocrine cell-derived tumour.  Garcia et al now show that β cell expression of the peptide hormone cholecystokinin is necessary and sufficient for obesity associated PDAC progression in mice and that CCK expression – rather than insulin – correlates strongly with enhanced tumourigenesis. Single-cell RNA-sequencing, in silico latent-space archetypal and trajectory analysis, and experimental lineage tracing in vivo reveal that obesity induces the expansion of postnatal immature β cells, which adapt to express CCK via stress-responsive JNK/cJun signaling. Finally, obesity perturbs CCK-dependent peri-islet exocrine cell transcriptional states and enhances islet-proximal tumor formation. These results define endocrine-exocrine CCK signaling as a bona fide driver of obesity-associated PDAC development and uncover avenues to target the endocrine pancreas to subvert exocrine tumourigenesis.

Read the full article >

See all cholecystokinin receptor modulators >

See all cancer research categories >